News

home News

[210917 저널발표] IL-17 triggers the onset of cognitive and synaptic deficits in early stages of Alzheimer’s disease

김행준 │ 2021-09-15

HIT

345

https://www.cell.com/cell-reports/fulltext/S2211-1247(21)01008-1

Highlights

  • IL-17-producing cells accumulate in the brain and the meninges of 3xTg-AD mice
  • The increase of IL-17 producers associates with short-term memory deficits
  • Neutralization of IL-17 prevents cognitive impairments and synaptic dysfunction
  • IL-17 triggers Alzheimer’s disease onset independently of Aβ and tau pathology

Summary

Neuroinflammation in patients with Alzheimer’s disease (AD) and related mouse models has been recognized for decades, but the contribution of the recently described meningeal immune population to AD pathogenesis remains to be addressed. Here, using the 3xTg-AD model, we report an accumulation of interleukin-17 (IL-17)-producing cells, mostly γδ T cells, in the brain and the meninges of female, but not male, mice, concomitant with the onset of cognitive decline. Critically, IL-17 neutralization into the ventricles is sufficient to prevent short-term memory and synaptic plasticity deficits at early stages of disease. These effects precede blood-brain barrier disruption and amyloid-beta or tau pathology, implying an early involvement of IL-17 in AD pathology. When IL-17 is neutralized at later stages of disease, the onset of short-memory deficits and amyloidosis-related splenomegaly is delayed. Altogether, our data support the idea that cognition relies on a finely regulated balance of “inflammatory” cytokines derived from the meningeal immune system.

Graphical abstract

Figure thumbnail fx1



Prev [210917 저널발표] Age-dependent instability of mature neuronal fate in induced n...
Next [210924 저널발표]Microbiota from young mice counteracts selective age-associated...